Cardiff Oncology
Logotype for Cardiff Oncology Inc

Cardiff Oncology (CRDF) investor relations material

Cardiff Oncology UBS Global Biopharma Conference 2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cardiff Oncology Inc
UBS Global Biopharma Conference 2026 summary16 Nov, 2026

First-line colorectal cancer opportunity and phase II findings

  • Onvansertib targets PLK1 in pan-RAS-mutated metastatic colorectal cancer; ~50% of patients have RAS mutations, and the speaker cited limited treatment innovation in this population over 20+ years.

  • In the randomized phase II CRDF-004 trial, onvansertib 30 mg plus FOLFOXIRI/bev showed ORR of 70%+ vs 42% with FOLFOXIRI/bev alone.

  • Median PFS was reached at ~11 months in the control arm but remained unreached with 30 mg onvansertib plus FOLFOXIRI/bev; the phase II study was small and not powered for PFS.

  • Tumor shrinkage and responses appeared durable; several patients in the 30 mg combination arm proceeded to curative surgery.

  • The 30 mg FOLFOXIRI/bev combination showed benefit trends across reported baseline subgroups; the speaker said this regimen had the strongest results and would advance to phase III.

Phase III and regulatory plans

  • FDA-aligned phase III plans compare onvansertib 30 mg plus FOLFOXIRI/bev with FOLFOXIRI/bev alone, enrolling patients across RAS mutations and powering the study for PFS and potential full approval.

  • The FDA will also allow ORR assessment for potential accelerated approval if results are compelling; Fast Track designation was announced shortly before the conference.

  • Trial initiation was targeted in a staged manner in Q1 2027, pending funding; a CRO had been selected, and regulatory work included manufacturing and companion diagnostic planning.

  • Cash was ~$34 million at Q3-end 2026, with expected runway through Q3 2027; European regulator feedback was awaited.

Other indications and pipeline

  • Relapsed/refractory CMML showed monotherapy activity, with responses cited at ~40%; an updated presentation was planned for the American Society of Hematology meeting in December 2026.

  • Orphan drug designations were received for CMML and small cell lung cancer; early monotherapy activity was also noted in small cell lung cancer.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Cardiff Oncology earnings date

Logotype for Cardiff Oncology Inc
Q4 202625 Feb, 2027
Cardiff Oncology
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Cardiff Oncology earnings date

Logotype for Cardiff Oncology Inc
Q4 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Cardiff Oncology Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative therapies for various cancers. The company's primary approach involves leveraging PLK1 (Polo-like Kinase 1) inhibition to create novel cancer treatments. Their flagship product, onvansertib, is an oral selective PLK1 inhibitor currently being evaluated in combination with standard-of-care therapeutics across several clinical programs. These include treatments for KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.